Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Rheumatology and Arthritis Learning Network or HMP Global, their employees, and affiliates.
Understand the efficacy and safety of RINVOQ, a once-daily oral JAK inhibitor, for the treatment of active psoriatic arthritis (PsA) in adult TNFi-IR patients.
Understand the efficacy and safety of RINVOQ, a once-daily oral JAK inhibitor, for the treatment of active psoriatic arthritis (PsA) in adult TNFi-IR patients.
A first biologic disease-modifying antirheumatic drug showed similar efficacy among psoriatic arthritis patients with a low number of affected joints as among those with a high number.
A first biologic disease-modifying antirheumatic drug showed similar efficacy among psoriatic arthritis patients with a low number of affected joints as among those with a high number.
The findings of a recent study suggest that menopause, particularly early menopause, may increase the risk of developing rheumatoid arthritis in women.
The findings of a recent study suggest that menopause, particularly early menopause, may increase the risk of developing rheumatoid arthritis in women.